Speaker Profile
Ph.D., PHARMD, Founder & CEO, Origenity
Biography
Donnacha Fitzgerald works at the intersection of artificial intelligence, single-cell omics, and cellular engineering to enable the design of novel cell states for therapeutics and biomanufacturing. His work focuses on using generative and predictive models to move from analyzing biology to designing it, enabling programmable control of cellular behavior. Before founding Origenity, he trained and worked across drug discovery, clinical practice, and regulatory science. During his doctoral research at the European Molecular Biology Laboratory, he combined single-cell and spatial omics to uncover cellular differentiation as a driver of tumor evolution. He also co-founded Nucleate Germany, now the countrys largest academic biotech entrepreneurship network, and advises the International Pharmaceutical Federation on emerging biotechnologies shaping pharmaceutical care. He is passionate about building technologies that expand humanitys capacity to engineer life.
Talk
AI-Guided Cell Design for Emerging Therapeutics
AI-guided cell design bridges single-cell omics, generative modeling, and cellular engineering to enable programmable control of biological function. This talk will outline how predictive models can guide the design and engineering of cellular states, unlocking new classes of genetic medicines and production cell lines while redefining the interface between computation and biology.
AI for Emerging Therapeutics Showcase:
Origenity
Origenity is building an AI-guided cell design platform that integrates single-cell omics, generative modeling, and cellular engineering to enable programmable control of biological function. The platform aims to unlock new classes of genetic medicines and optimized production cell lines for next-generation therapeutics and biomanufacturing.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2025AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
